Capstone Financial Advisors Inc. Reduces Position in Eli Lilly and Company (NYSE:LLY)

Capstone Financial Advisors Inc. decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 78.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 414 shares of the company's stock after selling 1,528 shares during the period. Capstone Financial Advisors Inc.'s holdings in Eli Lilly and Company were worth $320,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. CWA Asset Management Group LLC increased its holdings in shares of Eli Lilly and Company by 11.9% in the fourth quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after buying an additional 724 shares during the period. Knightsbridge Asset Management LLC increased its stake in Eli Lilly and Company by 1.9% in the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares during the period. Centerpoint Advisory Group bought a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $514,000. Kentucky Trust Co purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $834,000. Finally, CSM Advisors LLC grew its holdings in shares of Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after purchasing an additional 245 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of analyst reports. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Friday, January 17th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price target for the company from $1,150.00 to $700.00 in a research report on Monday. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday. Finally, Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,000.32.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Up 3.7 %

Shares of NYSE:LLY traded up $29.68 during trading on Friday, reaching $823.78. 4,597,327 shares of the stock traded hands, compared to its average volume of 3,867,996. The stock has a market cap of $781.08 billion, a P/E ratio of 70.35, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a 50-day moving average of $826.90 and a two-hundred day moving average of $816.98. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.58 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.